Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients with Metastatic Castration-Resistant Prostate Cancer
Rahul R. Aggarwal*, Jacqueline Vuky, David Vanderweele, Matthew Rettig, Elisabeth I. Heath, David Quigley, Jiaoti Huang, Arun Chumber, Alexander Cheung, Adam Foye, Stanley Leung, Jill Abbey, Andrew Dorr, Marc Nasoff, John Hunter, Steven Wang, Robert R. Flavell, Lawrence Fong, Bin Liu, Eric J. Small
Dive into the research topics of 'Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients with Metastatic Castration-Resistant Prostate Cancer'. Together they form a unique fingerprint.